Skip to main content

Nina Paulshu's Sundliseater

Postdoc
https://orcid.org/0000-0002-1295-0172
See Google Scholar profile
See publications in PubMed

Education

  • Cand.med at the University of Bergen
  • Specialist in rheumatology
  • Doctoral degree (PhD) at the Department of Clinical Medicine, University of Oslo

Score

  • Senior physician at the Department of Rheumatology, Outpatient Clinic and Research, Diakonhjemmet Hospital
  • Post doc, Clinic for rheumatology, outpatient clinic and research, Diakonhjemmet Hospital

Field of interest

  • Rheumatology
  • Outcome measures
  • Prediction
  • Follow-up and treatment
  • Randomized controlled trials

Email

Telephone

+47 22451500

visiting address

Diakonhjemmet hospital
Forstanderboligen
Reidar Kobros vei 8
0370 Oslo

Postal address

Diakohjemmet hospital
PO Box 23 Vinderen
0319 Oslo

Projects

WP1 - Optimized medical interventions

ARCTIC

Remission in patients with rheumatoid arthritis: a randomized controlled trial investigating the use of ultrasound in clinical follow-up

Project Manager:
Espen A. Haavardsholm
WP1 - Optimized medical interventions

ARCTIC REWIND

10-year follow-up of patients with rheumatoid arthritis who received structured treatment-to-target therapy in the early disease phase.

Project Manager:
Espen A. Haavardsholm
WP5 - Innovative approaches to remote care

NOR Flare

Distance follow-up of patients with rheumatoid arthritis

Project Manager:
Anne Therese Tveter

Publications

Publications taken from the National Science Archive (NVA):

Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomized controlled, non-inferiority trial

Kaja Eriksrud Kjørholt, Nina Paulshus Sundlisæter, Anna-Birgitte Aga, Joseph Sexton, Inge Christoffer Olsen, Hallvard Fremstad


The Lancet Rheumatology

2024

Performance of the Rheumatoid Arthritis Impact of Disease (RAID) score in relation to flares in disease activity

Karen Holten, Nina Paulshus Sundlisæter, Joseph Sexton, Lena Bugge Nordberg, Till Uhlig, Tore Kristian Aaserud Kvien


RMD Open

2024

Effect of tapered versus stable treatment with tumor necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial

Siri Lillegraven, Nina Paulshus Sundlisæter, Anna-Birgitte Aga, Joseph Sexton, Inge Christoffer Olsen, Åse Lexberg


Annals of the Rheumatic Diseases

2023

Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis and Excellent Disease Control

Siri Lillegraven, Nina Paulshus Sundlisæter, Anna-Birgitte Aga, Joseph Sexton, Daniel H. Solomon, Désirée Van Der Heijde


Journal of the American Medical Association (JAMA)

2023

Identification of SNPs associated with methotrexate treatment outcomes in patients with early rheumatoid arthritis

Shrikant Kolan, Gaoyang Li, Franco Grimolizzi, Joseph Sexton, Tore Kristian Kvien, Guro Løvik Goll


Frontiers in Pharmacology

2022

Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study

Nina Beate Paulshus Sundlisæter, Ulf Gunnar Sundin, Anna-Birgitte Aga, Joseph Sexton, Hilde Berner Hammer, Till Uhlig


RMD Open

2022

Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatment

Karen Holten, Nina Beate Paulshus Sundlisæter, Siri Lillegraven, Joseph Sexton, Lena Kristine Bugge Nordberg, Ellen Moholt


Annals of the Rheumatic Diseases

2021

Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients with Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial

Siri Lillegraven, Nina Beate Paulshus Sundlisæter, Anna-Birgitte Aga, Joseph Sexton, Inge Christoffer Olsen, Hallvard Fremstad


Journal of the American Medical Association (JAMA)

2021

Value of MRI and ultrasound for prediction of therapeutic response and erosive progression in patients with early rheumatoid arthritis managed by an aggressive treat-to-target strategy

Ulf Gunnar Sundin, Nina Beate Paulshus Sundlisæter, Anna-Birgitte Aga, Joseph Sexton, Lena Kristine Bugge Nordberg, Hilde Berner Hammer


RMD Open

2021

Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol

Nina Beate Paulshus Sundlisæter, Inge Christoffer Olsen, Anna-Birgitte Aga, Hilde Berner Hammer, Till Uhlig, Desirée van der Heijde


Rheumatology

2018

Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: Associations to future good radiographic and physical outcomes

Nina Beate Paulshus Sundlisæter, Anna-Birgitte Aga, Inge Christoffer Olsen, Hilde Berner Hammer, Till Uhlig, Desirée van der Heijde


Annals of the Rheumatic Diseases

2018

Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis

Maria Karolina Jonsson, Nina Beate Paulshus Sundlisæter, Hilde Haugedal Nordal, Hilde Berner Hammer, Anna-Birgitte Aga, Inge Christoffer Olsen


Annals of the Rheumatic Diseases

2017